Key Points
-
Various populations of B cells with immune-regulatory functions exist in mice and humans
-
Regulatory B (BREG) cells can control immune responses via diverse mechanisms, including cytokines, growth factors and cell–cell interactions
-
Immunosuppression-free renal transplant recipients have an altered B-cell compartment compared with patients on immunosuppression who have stable graft function, suggesting that B cells have a crucial role in immune-system regulation
-
BREG cells have therapeutic potential in animal models of transplantation
-
More investigation is required to elucidate the exact role of B cells in transplant tolerance and to develop strategies to expand BREG cell populations
Abstract
In transplantation, the contribution of B cells to the rejection or acceptance of the allograft is a topic of major interest. The presence of donor-specific antibodies in transplant recipients is often associated with decreased graft function and rejection, clearly indicating a pathogenetic role of B cells in transplantation. However, data from studies in humans and rodents suggest that under certain conditions, B cells have the capacity to control or regulate the immune response to a transplanted organ. Although a great deal of attention has been focused on B cells in human and murine models of autoimmunity, our understanding of the role of these cells in transplantation is limited at present. Indeed, results in this setting are controversial and seem to depend on the model system used or the clinical situation studied. Here, we review the current understanding of the various phenotypes and roles that have been associated with immune-regulating B cells. We also discuss the mechanisms employed by subsets of these regulatory B cells to control the immune response in transplant recipients and in animal models of transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jevnikar, A. M. & Mannon, R. B. Late kidney allograft loss: what we know about it, and what we can do about it. Clin. J. Am. Soc. Nephrol. 3 (Suppl. 2), S56–S67 (2008).
Bosmans, J. L. & Verpooten, G. A. Malignancy after kidney transplantation: still a challenge. Kidney Int. 71, 1197–1199 (2007).
Bottomley, M. J. & Harden, P. N. Update on the long-term complications of renal transplantation. Br. Med. Bull. 106, 117–134 (2013).
Sherston, S. N., Carroll, R. P., Harden, P. N. & Wood, K. J. Predictors of cancer risk in the long-term solid-organ transplant recipient. Transplantation 97, 605–611 (2014).
Wood, K. J., Bushell, A. & Hester, J. Regulatory immune cells in transplantation. Nat. Rev. Immunol. 12, 417–430 (2012).
Wood, K. J. & Goto, R. Mechanisms of rejection: current perspectives. Transplantation 93, 1–10 (2012).
Everly, M. J. et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9, 1063–1071 (2009).
Mizoguchi, E., Mizoguchi, A., Preffer, F. I. & Bhan, A. K. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int. Immunol. 12, 597–605 (2000).
Tian, J. et al. Lipopolysaccharide-activated B cells down-regulate TH1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167, 1081–1089 (2001).
Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944–950 (2002).
Cooper, M. D., Peterson, R. D. & Good, R. A. Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 205, 143–146 (1965).
Osmond, D. G. B cell development in the bone marrow. Semin. Immunol. 2, 173–180 (1990).
Schatz, D. G. & Baltimore, D. Uncovering the V(D)J recombinase. Cell 116 (Suppl. 2), S103–S106 (2004).
Tiegs, S. L., Russell, D. M. & Nemazee, D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177, 1009–1020 (1993).
Loder, F. et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J. Exp. Med. 190, 75–89 (1999).
Merrell, K. T. et al. Identification of anergic B cells within a wild-type repertoire. Immunity 25, 953–962 (2006).
Zouali, M. The epigenetic landscape of B lymphocyte tolerance to self. FEBS Lett. 587, 2067–2073 (2013).
Mauri, C. & Bosma, A. Immune regulatory function of B cells. Annu. Rev. Immunol. 30, 221–241 (2012).
Dalwadi, H. et al. B cell developmental requirement for the Gαi2 gene. J. Immunol. 170, 1707–1715 (2003).
Lampropoulou, V. et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180, 4763–4773 (2008).
Yanaba, K., Bouaziz, J. D., Matsushita, T., Tsubata, T. & Tedder, T. F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182, 7459–7472 (2009).
Zhang, X. Regulatory functions of innate-like B cells. Cell. Mol. Immunol. 10, 113–121 (2013).
O'Garra, A. et al. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22, 711–717 (1992).
Spencer, N. F. & Daynes, R. A. IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5− B cells: possible involvement in age-associated cytokine dysregulation. Int. Immunol. 9, 745–754 (1997).
Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. & Bhan, A. K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16, 219–230 (2002).
Lenert, P., Brummel, R., Field, E. H. & Ashman, R. F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25, 29–40 (2005).
Mauri, C., Gray, D., Mushtaq, N. & Londei, M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197, 489–501 (2003).
Evans, J. G. et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol. 178, 7868–7878 (2007).
Kalampokis, I., Yoshizaki, A. & Tedder, T. F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15 (Suppl. 1), S1 (2013).
Ding, Q. et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121, 3645–3656 (2011).
Rafei, M. et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15, 1038–1045 (2009).
Blair, P. A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129–140 (2010).
Iwata, Y. et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530–541 (2011).
Lemoine, S., Morva, A., Youinou, P. & Jamin, C. Human T cells induce their own regulation through activation of B cells. J. Autoimmun. 36, 228–238 (2011).
Neves, P. et al. Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection. Immunity 33, 777–790 (2010).
Yanaba, K. et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639–650 (2008).
Cohen-Sfady, M. et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J. Immunol. 175, 3594–3602 (2005).
Deng, S. et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J. Immunol. 178, 6028–6032 (2007).
Mann, M. K., Maresz, K., Shriver, L. P., Tan, Y. & Dittel, B. N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 178, 3447–3456 (2007).
Gillan, V., Lawrence, R. A. & Devaney, E. B cells play a regulatory role in mice infected with the L3 of Brugia pahangi. Int. Immunol. 17, 373–382 (2005).
Sato, S., Ono, N., Steeber, D. A., Pisetsky, D. S. & Tedder, T. F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157, 4371–4378 (1996).
Martin, F. & Kearney, J. F. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity 12, 39–49 (2000).
Matsumoto, M. et al. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 34, 703–714 (2011).
Bhattacharyya, S. et al. NFATc1 affects mouse splenic B cell function by controlling the calcineurin--NFAT signaling network. J. Exp. Med. 208, 823–839 (2011).
Yoshizaki, A. et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491, 264–268 (2012).
Yang, M. et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol. 184, 3321–3325 (2010).
Gray, M., Miles, K., Salter, D., Gray, D. & Savill, J. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc. Natl Acad. Sci. USA 104, 14080–14085 (2007).
Blair, P. A. et al. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol. 182, 3492–3502 (2009).
Carter, N. A. et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of TH1/TH17 but a decrease in regulatory T cells. J. Immunol. 186, 5569–5579 (2011).
Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420–3430 (2008).
Hoehlig, K. et al. Activation of CD4+ Foxp3+ regulatory T cells proceeds normally in the absence of B cells during EAE. Eur. J. Immunol. 42, 1164–1173 (2012).
Yang, M. et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing TH17 cell generation. Am. J. Pathol. 180, 2375–2385 (2012).
Carter, N. A., Rosser, E. C. & Mauri, C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14, R32 (2012).
Moulin, V. et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192, 475–482 (2000).
Matsushita, T., Horikawa, M., Iwata, Y. & Tedder, T. F. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J. Immunol. 185, 2240–2252 (2010).
Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170–181 (2010).
Zhao, G. et al. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am. J. Transplant. 10, 796–801 (2010).
Parekh, V. V. et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-β 1. J. Immunol. 170, 5897–5911 (2003).
Natarajan, P. et al. Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-β, and co-localize with CD4+Foxp3+ T cells. Mucosal Immunol. 5, 691–701 (2012).
Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366–370 (2014).
Anel, A. et al. Apo2L/TRAIL and immune regulation. Front. Biosci. 12, 2074–2084 (2007).
Sharpe, A. H., Wherry, E. J., Ahmed, R. & Freeman, G. J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239–245 (2007).
Ray, A., Basu, S., Williams, C. B., Salzman, N. H. & Dittel, B. N. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J. Immunol. 188, 3188–3198 (2012).
Vas, J., Gronwall, C., Marshak-Rothstein, A. & Silverman, G. J. Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum. 64, 3388–3398 (2012).
Chen, Y. et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J. Immunol. 183, 1346–1359 (2009).
Kawano, T. et al. CD1d-restricted and TCR-mediated activation of VA14 NKT cells by glycosylceramides. Science 278, 1626–1629 (1997).
Sonoda, K. H. & Stein-Streilein, J. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur. J. Immunol. 32, 848–857 (2002).
Bialecki, E. et al. Role of marginal zone B lymphocytes in invariant NKT cell activation. J. Immunol. 182, 6105–6113 (2009).
Croxford, J. L., Miyake, S., Huang, Y. Y., Shimamura, M. & Yamamura, T. Invariant Vα19i T cells regulate autoimmune inflammation. Nat. Immunol. 7, 987–994 (2006).
Bosma, A., Abdel-Gadir, A., Isenberg, D. A., Jury, E. C. & Mauri, C. Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells. Immunity 36, 477–490 (2012).
Gregori, S. et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116, 935–944 (2010).
Yan, Y. et al. Postoperative administration of donor B cells induces rat kidney allograft acceptance: lack of association with TH2 cytokine expression in long-term accepted grafts. Transplantation 73, 1123–1130 (2002).
Liu, C. et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat. Med. 13, 1295–1298 (2007).
Le Texier, L. et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am. J. Transplant. 11, 429–438 (2010).
Fehr, T. et al. Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II. J. Immunol. 181, 165–173 (2008).
Fehr, T. et al. Rapid deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells. J. Immunol. 181, 4371–4380 (2008).
Huang, X. et al. Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance. Transplantation 85, 675–680 (2008).
Xiao, S. et al. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J. Exp. Med. 204, 1691–1702 (2007).
DiLillo, D. J. et al. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J. Immunol. 186, 2643–2654 (2011).
Newell, K. A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836–1847 (2010).
Sagoo, P. et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120, 1848–1861 (2010).
Pallier, A. et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 78, 503–513 (2010).
Silva, H. M. et al. Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol. Med. 18, 733–743 (2012).
Chesneau, M. et al. Unique B cell differentiation profile in tolerant kidney transplant patients. Am. J. Transplant. 14, 144–155 (2014).
Haneda, M. et al. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 97, 405–412 (2014).
Brouard, S. et al. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am. J. Transplant. 12, 3296–3307 (2012).
Clatworthy, M. R. et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360, 2683–2685 (2009).
Deng, J. & Galipeau, J. Reprogramming of B cells into regulatory cells with engineered fusokines. Infect. Disord. Drug Targets 12, 248–254 (2012).
Van de Velde, H., von Hoegen, I., Luo, W., Parnes, J. R. & Thielemans, K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 351, 662–665 (1991).
Bikah, G., Carey, J., Ciallella, J. R., Tarakhovsky, A. & Bondada, S. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274, 1906–1909 (1996).
Depoil, D. et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat. Immunol. 9, 63–72 (2008).
Henchoz-Lecoanet, S. et al. The Epstein–Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells. Immunology 88, 35–39 (1996).
Tedder, T. F., Zhou, L. J. & Engel, P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 15, 437–442 (1994).
Spiegelberg, H. L. Fcε R2/CD23: its discovery and possible functions. Monogr. Allergy 29, 1–8 (1991).
Liu, Y. et al. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J. Exp. Med. 175, 437–445 (1992).
Allman, D. M., Ferguson, S. E. & Cancro, M. P. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J. Immunol. 149, 2533–2540 (1992).
Sims, G. P. et al. Identification and characterization of circulating human transitional B cells. Blood 105, 4390–4398 (2005).
Acknowledgements
The authors' work is funded by grants from the Wellcome Trust, UK Medical Research Council, British Heart Foundation and European Union through the ONE Study, Translating Research into Action for Diabetes (TRIAD) and Biomarker Driven Personal Immunosuppression (Bio-DRIM) projects, and the Immune Tolerance Network.
Author information
Authors and Affiliations
Contributions
J.S. researched the data for the article. J.S. and K.J.W. provided substantial contributions to discussions of the article content and wrote the manuscript. All authors undertook review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
J.S. and K.J.W. declare no competing interests. L.A.T. has a spouse employed by, and owns equity in, Novartis.
Rights and permissions
About this article
Cite this article
Stolp, J., Turka, L. & Wood, K. B cells with immune-regulating function in transplantation. Nat Rev Nephrol 10, 389–397 (2014). https://doi.org/10.1038/nrneph.2014.80
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.80
This article is cited by
-
Biomarkers of immune tolerance in kidney transplantation: an overview
Pediatric Nephrology (2022)
-
The pursuit of transplantation tolerance: new mechanistic insights
Cellular & Molecular Immunology (2019)
-
New Steps in the Use of Mesenchymal Stem Cell in Solid Organ Transplantation
Current Transplantation Reports (2015)